Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Speetjens FM, Welters MJP, Slingerland M, van Poelgeest MIE, de Vos van Steenwijk PJ, Roozen I, Boekestijn S, Loof NM, Zom GG, Valentijn ARPM, Krebber WJ, Meeuwenoord NJ, Janssen CAH, Melief CJM, van der Marel GA, Filippov DV, van der Burg SH, Gelderblom H, Ossendorp F.
Speetjens FM, et al. Among authors: melief cjm.
J Immunother Cancer. 2022 Oct;10(10):e005016. doi: 10.1136/jitc-2022-005016.
J Immunother Cancer. 2022.
PMID: 36261215
Free PMC article.
Clinical Trial.